Compounds / Tesamorelin

Tesamorelin

Also known as: Egrifta (brand), TH9507

Established human clinical FDA-approved (brand product) Category: Growth Hormone Secretagogues

The compounds described in this library are research-use-labeled chemicals and are not FDA-approved for human use. This content is factual scientific reference drawn from published literature. It is not medical, dosing, or purchasing advice. VialReport does not sell, supply, or distribute any compound.

Short summary

A synthetic GHRH analogue approved by the FDA under the brand name Egrifta for reduction of excess visceral abdominal fat in patients with HIV-associated lipodystrophy. One of the few compounds in this library with a current FDA approval.

Dive deeper

Origin and Development

Developed as a stabilized analogue of human GHRH(1-44) with an added trans-3-hexenoyl group at the N-terminus, which improves resistance to enzymatic degradation. Developed by Theratechnologies and approved by the FDA in 2010.

Mechanism as Understood in the Literature

GHRH receptor agonist, stimulating endogenous growth hormone release. Its approved indication rests on the observed effect of that signaling on visceral adipose tissue specifically.

Research Status

Well characterized. Approval was supported by randomized controlled trials in HIV-associated lipodystrophy, and subsequent published work has examined effects on visceral fat and hepatic fat in other populations. This is a conventionally developed pharmaceutical.

Regulatory status · approved

FDA-approved as a prescription medicine under several brand names.

Approved indications and formulations differ by brand.

Material sold outside the approved supply chain is not the approved product, regardless of how it is labeled.

Commonly Confused With

Distinct from sermorelin and CJC-1295, though all three are GHRH analogues. Tesamorelin is based on the full GHRH(1-44) sequence with an N-terminal modification, rather than the truncated 1-29 fragment the others are built on.

How This Compound Is Marketed

Vendor marketing for this compound typically references visceral fat reduction and body composition, generally without reference to the narrow approved indication. VialReport does not evaluate or endorse these claims. See Research Status above for what the published literature actually establishes.

Analytical Profile

44 amino acids with an N-terminal trans-3-hexenoyl modification, molecular weight approximately 5136 Da for the free peptide; the acetate salt differs, and reported masses should state which form is meant. Substantially larger than the GHRH(1-29) analogues and readily distinguished from them by mass.

Stability and Handling

The approved product is supplied as a lyophilized powder for reconstitution with defined storage requirements.

Key Literature

  1. 01 Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370.
  2. 02 Stanley TL, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380-389.

VialReport publishes factual reference information and independent test data. Nothing here is medical, dosing, or purchasing advice.

Published reports

Reports for Tesamorelin

No reports for this compound yet.

Want a vendor’s version of this compound tested? Request it and we’ll notify you when a report publishes.

Request a test

Stay current

Get notified when new reports publish.

No membership required. We email findings when they're published. Not updates, not promotions, just reports.

Powered by MailerLite. No spam. Unsubscribe anytime.